Literature DB >> 8049462

Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen.

J Lukac1, Z Kusić, D Kordić, M Koncar, A Bolanca.   

Abstract

The number of leukocytes, proportion and absolute number of granulocytes, lymphocytes, CD4+ cells, CD8+ cells, CD16+ cells, B-lymphocytes, monocytes, natural killer cell (NK) activity, and granulocyte and monocyte phagocytic functions--ingestion and intracellular killing--were determined in a group of 27 patients with ductal invasive breast carcinoma, stage I-III, before and 7 months following postsurgical telecobalt radiotherapy, divided into two subgroups, one of them receiving tamoxifen (TMX group) and the other one not receiving any further therapy (control group). In control group, proportion of all lymphocytes and CD8+ cells as well as absolute number of all lymphocytes, CD4+, CD8+, CD16+ and B lymphocytes were decreased following TCT in comparison to their pre-TCT values, while in TMX group only absolute number of all lymphocytes remained decreased following TCT. Moreover, post-TCT proportions of all and CD8+ lymphocytes as well as absolute numbers of all and CD4+ and CD8+ lymphocytes in TMX patients were significantly increased in comparison to the same parameters in control post-TCT patients, although there was no difference between the two subgroups before TCT. At the other hand, granulocyte ingestion was decreased in post-TCT TMX patients compared to post-TCT values in control patients and NK cell activity showed a similar, although statistically not significant, tendency. It seems that TMX helps recovery of lymphocyte populations decreased by radiotherapy, probably by stimulation of cells carrying estrogen receptors, but its effects on phagocytic functions and probably NK cell activity seemed to be rather inhibitory than stimulatory.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049462     DOI: 10.1007/bf00666482

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.

Authors:  M Pollak; J Costantino; C Polychronakos; S A Blauer; H Guyda; C Redmond; B Fisher; R Margolese
Journal:  J Natl Cancer Inst       Date:  1990-11-07       Impact factor: 13.506

Review 2.  Immunotherapy of breast cancer: a review of the development of cell-specific therapy.

Authors:  G H Lytle
Journal:  Semin Surg Oncol       Date:  1991 Jul-Aug

3.  Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen.

Authors:  V C Jordan
Journal:  J Natl Cancer Inst       Date:  1990-11-07       Impact factor: 13.506

4.  Assessment of blood leukocyte microbial killing by using a new fluorochrome microassay.

Authors:  C G Pantazis; W T Kniker
Journal:  J Reticuloendothel Soc       Date:  1979-08

5.  A simple microscopic method for identifying and quantitating phagocytic cells in vitro.

Authors:  J Patterson-Delafield; R I Lehrer
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

6.  In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen)

Authors:  R Mandeville; S S Ghali; J P Chausseau
Journal:  Eur J Cancer Clin Oncol       Date:  1984-07

7.  Changes in T-cell subsets after radiation therapy.

Authors:  S J Yang; S Rafla; E Youssef; H Selim; N Salloum; J Y Chuang
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

8.  Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer.

Authors:  J Berry; B J Green; D S Matheson
Journal:  Eur J Cancer Clin Oncol       Date:  1987-05

9.  Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry.

Authors:  M L Graham; J A Smith; P B Jewett; K B Horwitz
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

Review 10.  Potential role of tamoxifen in prevention of breast cancer.

Authors:  S G Nayfield; J E Karp; L G Ford; F A Dorr; B S Kramer
Journal:  J Natl Cancer Inst       Date:  1991-10-16       Impact factor: 13.506

View more
  3 in total

Review 1.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

2.  Immune response, depression and fatigue in relation to support intervention in mammary cancer patients.

Authors:  Christina Lindemalm; Fariba Mozaffari; Aniruddha Choudhury; Helena Granstam-Björneklett; Mats Lekander; Bo Nilsson; Marja-Leena Ojutkangas; Anders Osterborg; Leif Bergkvist; Håkan Mellstedt
Journal:  Support Care Cancer       Date:  2007-06-12       Impact factor: 3.603

3.  Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.

Authors:  A Decensi; C Robertson; N Rotmensz; G Severi; P Maisonneuve; V Sacchini; P Boyle; A Costa; U Veronesi
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.